First mRNA Flu Vaccine Introduced, Targeting Specific Age Groups

Why it matters locally: The introduction of an mRNA flu vaccine provides Maine residents with a new option for influenza prevention, potentially impacting public health strategies and vaccine accessibility across the state.

An mRNA flu vaccine has become available, offering an alternative to traditional flu shots this fall. This new vaccine is not universally accessible; specific age groups qualify for its use. Manufacturers developed the mRNA vaccine using a different technological approach compared to conventional flu vaccines. This method focuses on instructing the body's cells to produce a protein that triggers an immune response against the influenza virus. Individuals seeking this new mRNA option should consult their healthcare providers to determine eligibility. Providers will assess age and other criteria to confirm suitability for the vaccine. The introduction of this vaccine expands the range of available options for flu season preparedness.